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Abstract
Background: Predicting treatment benefit and/or outcome before any therapeutic intervention has taken place
would be clinically very useful. Herein, we evaluate the ability of the intrinsic subtypes and the risk of relapse score
at diagnosis to predict survival and response following neoadjuvant chemotherapy. In addition, we evaluated the
ability of the Claudin-low and 7-TNBCtype classifications to predict response within triple-negative breast
cancer (TNBC).
Methods: Gene expression and clinical-pathological data were evaluated in a combined dataset of 957 breast
cancer patients, including 350 with TNBC, treated with sequential anthracycline and anti-microtubule-based
neoadjuvant regimens. Intrinsic subtype, risk of relapse score based on subtype and proliferation (ROR-P), the
Claudin-low subtype and the 7-TNBCtype subtype classification were evaluated. Logistic regression models for
pathological complete response (pCR) and Cox models for distant relapse-free survival (DRFS) were used.
Results: Basal-like, Luminal A, Luminal B, and HER2-enriched subtypes represented 32.7 %, 30.6 %, 18.2 %, and 10.3 % of
cases, respectively. Intrinsic subtype was independently associated with pCR in all patients, in hormone receptor-positive/
HER2-negative disease, in HER2-positive disease, and in TNBC. The pCR rate of Basal-like disease was >35 % across all
clinical cohorts. Neither the Claudin-low nor the 7-TNBCtype subtype classifications predicted pCR within TNBCs
after accounting for intrinsic subtype. Finally, intrinsic subtype and ROR-P provided independent prognostic
information beyond clinicopathological variables and type of pathological response. A 5-year DRFS of 97.5 %
(92.8–100.0 %) was observed in these neoadjuvant-treated and clinically node-negative patients predicted to be
low risk by ROR-P (i.e. 57.4 % of Luminal A tumors with clinically node-negative disease).
Conclusions: Intrinsic subtyping at diagnosis provides prognostic and predictive information for patients receiving
neoadjuvant chemotherapy. Although we could not exclude a survival benefit of neoadjuvant chemotherapy in patients
with early breast cancer with clinically node-negative and ROR-low disease at diagnosis, the absolute benefit of cytotoxic
therapy in this group might be rather small (if any).
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Background
During the last decade, it has become apparent that
gene expression-based data in breast cancer can pro-
vide useful biological, prognostic, and predictive informa-
tion [1, 2]. For example, the main intrinsic molecular
subtypes of breast cancer (Luminal A, Luminal B, HER2-
enriched, and Basal-like) are biologically and prognos-
tically relevant [3–6] and have been associated with
anthracycline and tamoxifen benefit in the adjuvant set-
ting [7–9]. Importantly, the intrinsic subtypes are not
fully recapitulated by the combined determination of
pathology-based biomarkers such as estrogen receptor
(ER), progesterone receptor (PR), Ki67, and HER2 [1, 3,
4, 9–12], all of which are currently being used in the
clinical setting. Thus, from a clinical perspective, there is
a need to understand the value of identifying the intrinsic
subtypes, as well as other gene expression-based classifica-
tions, beyond clinicopathological variables.
We have previously shown that all the intrinsic sub-
types can be identified within various clinically-defined
groups, albeit with different proportions [9, 11, 13, 14].
For example, although the Basal-like subtype predomi-
nates within triple-negative breast cancer (TNBC), all
the intrinsic subtypes can be identified in TNBC, and
identification of the ‘Basal-like versus not’ classification
within TNBC might be clinically relevant [15, 16]. Beyond
the main subtypes of breast cancer, we have also reported
the Claudin-low subtype characterized by the low to ab-
sent expression of luminal differentiation markers, and by
the high enrichment for epithelial-to-mesenchymal transi-
tion markers, immune response genes, and cancer stem
cell-like features [4]. In a previous report, Claudin-low
tumors showed an intermediate pathological complete
response (pCR) rate compared to Basal-like tumors in a
cohort of 133 patients with TNBC and non-TNBC tumors
treated with anthracycline/taxane-based chemotherapy [4].
Recently, Lehmann et al. [17] reported the identifica-
tion of seven different potential molecular subtypes of
TNBC (Basal 1 (BL1), Basal 2 (BL2), Immunomodula-
tory, Luminal androgen receptor (LAR), Mesenchymal,
Mesenchymal stem cell (MSL), and unstable UNS). This
seven-subtype classification of TNBC was found to be
associated with pCR in an independent cohort of 130
TNBC patients treated with anthracycline/taxane-based
chemotherapy [18]. Among the different subtypes, BL2
and LAR subtypes showed the lowest pCR rates, and
BL1 showed the highest pCR rates, compared to the
other subtypes [18].
In this study, we evaluated the ability of the common
PAM50 intrinsic subtypes, and the risk of relapse score
based on subtype and proliferation (ROR-P), to predict
response and survival outcomes beyond standard clinical-
pathological variables following neoadjuvant multi-agent
chemotherapy. In addition, we evaluated the ability of the
Claudin-low [4] and the seven TNBC subtype classifica-
tions [17] to predict pCR within TNBC. Finally, we trained
and tested gene expression-based models predictive of
pCR in all patients, in patients with Basal-like disease, and
in patients with Luminal disease, to identify some of
the driving biological features behind response within
these groups.
Methods
Patients, samples and clinical data
Four clinically annotated microarray-based breast can-
cer datasets were evaluated from the public domain
(GSE25066 [19], GSE32646 [20], GSE41998 [21], and
GSE22226 [22]). All patients received sequential anthracy-
cline and taxane/exabepilone-based neoadjuvant regimens.
Patients that received trastuzumab were excluded. All gene
expression microarray-based analyses were performed in
pre-treatment tumor samples. The total number of pa-
tients included in this analysis was 957 (Additional file 1:
Figure S1). Ethical approval and informed consent were
not required for this study.
The Hatzis et al. [19] dataset includes 508 patients
treated with sequential anthracycline and taxane-based
chemotherapy in various research protocols: LAB99-402,
USO-02-103, 2003-0321, and I-SPY-1. A total of 508 pa-
tients from the Hatzis et al. [19] dataset have follow-up
data. Patients with any nuclear immunostaining of ER in
the tumor cells were considered eligible for adjuvant
endocrine therapy. In Horak et al. [21], 279 patients
were randomized to four cycles of doxorubicin/cyclo-
phosphamide followed by 1:1 randomization to either
ixabepilone 40 mg/m2 every 3 weeks for four cycles or
weekly paclitaxel 80 mg/m2 for 12 weeks, followed by
either weekly paclitaxel or exabepilone for 3 months. In
Miyake et al. [20], 115 patients received paclitaxel
(80 mg/m2) weekly for 12 cycles followed by 5-FU
(500 mg/m2), epirubicin (75 mg/m2) and cyclophospha-
mide (500 mg/m2) every 3 weeks for four cycles.
Finally, Essermann et al. [22] included 149 patients
treated in the ISPY-1 clinical trial with doxorubicin/
cyclophosphamide followed by paclitaxel. In this data-
set, we excluded 80 patients that were already included
in Hatzis et al. [19], one patient that received doxorubicin/
cyclophosphamide-only, and 13 patients that received
trastuzumab.
Pathology-based subtype definitions
We used the pathological ER, PR, and HER2 statuses of
each tumor sample as provided in each dataset [19–22].
The following pathology-based subtype definitions were
evaluated: hormone receptor (HR)+/HER2–, HER2+,
and TNBC.
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Pathological complete response (pCR) definition
pCR across all cohorts was defined as the percentage of
patients with no histologic evidence of residual invasive
carcinoma in the breast and axillary lymph nodes, re-
gardless of the presence or absence of ductal carcinoma
in situ.
Identification of the intrinsic subtypes
In each dataset, all tumors were assigned to an intrin-
sic molecular subtypes of breast cancer (Luminal A,
Luminal B, HER2-enriched, Basal-like) and the Normal
breast-like group using the PAM50 subtype predictor
as previously described [4, 22–24]. For the ISPY-1 [22]
and Miyake [20] cohorts, we used the previously re-
ported subtype calls [22, 25]. In addition, we evaluated
the previously reported ROR-P score [23]. To identify
the Claudin-low subtype [4] in TNBC, we applied the nine
cell-line Claudin-low predictor in each microarray dataset
using all patients as previously described [4]. TNBCs that
were identified as Claudin-low were considered Claudin-
low regardless of the intrinsic subtype call.
Identification of subtypes within TNBC
To identify the seven TNBC subtypes described by
Lehmann et al. [17], we first selected the TNBCs from
each dataset. Secondly, we submitted the raw data of
each individual dataset to the TNBCtype online pre-
dictor (http://cbc.mc.vanderbilt.edu/tnbc/) [26]. The
TNBCtype tool first checks the levels of the ER gene
(ESR1) across all TNBCs, and identifies those samples
with a relative high ESR1 expression level. These ESR-
high TNBCs need to be removed from each dataset in
order for the TNBCtype predictor algorithm to continue.
Training and testing gene expression-based models
We explored the ability of newly derived gene expression-
based models to predict pCR in three different cohorts: all
patients, patients with Basal-like disease, and patients with
Luminal disease (Luminal A and B combined). To build
each model, we explored the expression of 378 different
gene signatures (Additional file 2: Supplemental Data) and
used Elastic Net building model by 10 cross-validations.
To accomplish this, we used the MDACC-based cohort
(GSE25066 [19]) as a training set where each model
was derived in each cohort, and then tested this exact
model in the same clinical cohorts on the other data-
sets (testing sets). To estimate the performance of each
model, we used the area under the receiver operating
characteristic (auROC) curves.
Statistical analysis
Biologic analysis of the gene list was performed with
DAVID annotation tool (http://david.abcc.ncifcrf.gov/)
[27]. Association between subtype and pCR was assessed
by univariate and multivariable logistic regression ana-
lysis. Likelihood ratio tests were used to assess if a vari-
able added predictive information to each model. To
estimate the predictive performance of each variable,
auROC curves were evaluated. Survival functions to dis-
tant relapse-free survival (DRFS) were from the Kaplan-
Meier product-limit estimator with tests of differences
by the log-rank test. Cox proportional hazard models ad-
justed for standard clinical-pathological variables were
used to test the independent associations with survival
of each variable. Reported P values are two-sided.
Results
Clinical-pathological characteristics of the combined
cohort
A total of 957 patients with breast cancer treated with
sequential anthracycline and taxane/ixabepilone-based
neoadjuvant regimens were included in the analysis
(Table 1). All datasets included all clinicopathological
variables, except for histological grade and nodal status
in Horak et al. [19] and nodal status in ISPY-1 et al. [22]
since these were not provided. The mean age was
50.0 years and most patients had tumors of less than
5 cm (61.3 % T0-T2) and positive axillary nodal status
by clinical assessment (69.7 %). Pathology-based subtype
distribution was as follows: 494 (52.7 %) HR+/HER2–, 93
(9.9 %) HER2+, and 350 (37.4 %) TNBCs.
Intrinsic subtype and ROR-P associations with survival
outcome
A total of 508 patients from Hatzis et al. [19] had
follow-up data (mean 2.98 years). In this dataset, both
intrinsic subtype and ROR-P were found to be signifi-
cantly associated with DRFS in univariate and multivari-
able analyses after adjustment for age, tumor size, nodal
status, ER and PR status, HER2 status, histological
grade, and tumor response (pCR vs. residual disease)
(Additional file 1: Table S1 and S2). Of note, a 5-year
DRFS rate of 90.2 % (95 % confidence interval (CI),
82.5–98.6 %) was observed in patients whose tumors
were predicted to be low risk by ROR-P (Additional file 1:
Figure S2A). This 5-year DRFS rate increased to 97.5 %
(95 % CI, 92.78–100.0 %) in patients with ROR-P low
disease that presented with clinically node-negative
disease (Additional file 1: Figure S2B).
Next, we evaluated the survival outcomes based on
the type of pathological response. Within patients that
achieved a pCR, no variable was found to be signifi-
cantly associated with DRFS in univariate analyses
(Fig. 1a and b; Additional file 1: Tables S3 and S4).
Within patients that did not achieve a pCR, both intrin-
sic subtype and ROR-P were found to be significantly
associated with DRFS in univariate and multivariable ana-
lyses after adjustment for the other clinicopathological
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variables (Fig. 1c and d and Table 2; Additional file 1:
Table S5). Among them, tumor size and nodal status
before treatment were significantly associated with DRFS.
Finally, high 5-year DRFS rates were observed as in the
global population in patients with ROR-P low disease that
did not achieve a pCR (5-year DRFS of 92.0 % (95 % CI,
85.5–99.1 %) in all patients and of 97.4 % (95 % CI, 92.6–
100.0 %) in node-negative disease). No statistically signifi-
cant interaction (P = 0.430) was observed between ROR-P
(as a continuous variable) and pCR in DRFS analysis.
Intrinsic subtype association with chemotherapy response
in all patients
The pCR rates across the intrinsic molecular subtypes
were 6 %, 16 %, 37 %, and 38 % for the Luminal A,
Luminal B, HER2-enriched, and Basal-like subtypes,
respectively. In a multivariable model, the intrinsic sub-
types were independently associated with pCR after
adjustment for age, tumor size, ER and PR statuses,
histological grade, HER2 status, and study (Table 3 and
Additional file 1: Table S6). Of note, ER and PR status
Table 1 Clinicopathological characteristics and subtype distribution of the combined cohort evaluated in this study
GSE41998 [21] % GSE25066 [19] % GSE32646 [20] % GSE22226 [22] % TOTAL %
N 279 – 508 – 115 – 55 – 957 –
Age, years (mean) 49 – 50 – 51 – 49 – 50 –
Tumor size
T0-T2 177 64.1 % 288 56.7 % 92 80 % 27 50.0 % 584 61.3 %
T3-T4 99 35.9 % 220 43.3 % 23 20 % 27 50.0 % 369 38.7 %
ER IHC status
Positive 108 38.7 % 297 59.2 % 71 62 % 31 58.5 % 507 53.4 %
Negative 171 61.3 % 205 40.8 % 44 38 % 22 41.5 % 442 46.6 %
PR IHC status
Positive 99 35.6 % 243 48.5 % 45 39 % 21 39.6 % 408 43.1 %
Negative 179 64.4 % 258 51.5 % 70 61 % 32 60.4 % 539 56.9 %
Triple-negative status
No 139 49.8 % 330 65.0 % 89 77 % 47 88.7 % 605 63.4 %
Yes 140 50.2 % 178 35.0 % 26 23 % 6 11.3 % 350 36.6 %
HER2 IHC/FISH status
Negative 251 90.0 % 485 98.8 % 81 70 % 24 49.0 % 841 90.0 %
Positive 28 10.0 % 6 1.2 % 34 30 % 25 51.0 % 93 10.0 %
Histological grade
1 – – 32 6.8 % 16 13.9 % 2 3.6 % 50 14.9 %
2 – – 180 38.2 % 78 67.8 % 27 49.1 % 285 48.2 %
3 – – 259 55.0 % 21 18.3 % 26 47.3 % 306 51.8 %
Nodal status
N0 – – 157 31 % 32 28 % – – 189 30.3 %
N1-3 – – 351 69 % 83 72 % – – 434 69.7 %
pCR rate
No 184 72.7 % 389 79.7 % 88 77 % 37 68.5 % 698 76.7 %
Yes 69 27.3 % 99 20.3 % 27 23 % 17 31.5 % 212 23.3 %
PAM50
Luminal A 91 32.6 % 155 30.5 % 30 26 % 17 30.9 % 293 30.6 %
Luminal B 33 11.8 % 109 21.5 % 23 20 % 9 16.4 % 174 18.2 %
HER2-E 23 8.2 % 40 7.9 % 24 21 % 12 21.8 % 99 10.3 %
Basal-like 110 39.4 % 171 33.7 % 21 18 % 11 20.0 % 313 32.7 %
Normal-like 22 7.9 % 33 6.5 % 17 15 % 6 10.9 % 78 8.2 %
HER2-E, HER2-enriched; pCR, Pathological complete response; ER, Estrogen receptor; PR, Progesterone receptor; IHC, Immunohistochemistry
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by immunohistochemistry (IHC) did not provide inde-
pendent predictive information once intrinsic subtype
was introduced into the model.
pCR rates of the intrinsic subtypes across
pathology-defined subgroups
The intrinsic subtype classification was independently
associated with pCR within HR+/HER2–, HER2+, and
TNBC clinical subgroups (Table 4). Non-luminal (Basal-
like and HER2-enriched) tumors, as a group, showed
higher pCR rates than luminal (Luminal A and B) tumors
in HR+/HER2– (30.0 % vs. 8.9 %, adjusted OR = 4.20,
2.220–7.942), HER2+ (45.8 % vs. 14.3 %, adjusted OR =
5.22, 1.478–18.460), and TNBC (38.5 % vs. 18.5 %,
adjusted OR = 2.89, 1.043–8.003) diseases. Among the dif-
ferent subtypes, the Basal-like subtype showed consistent
pCR rates above 35 % across the three clinically-defined
subgroups (36 %, 58 %, and 37 % in HR+/HER2–, HER2+,
and TN subgroups, respectively). Finally, addition of
the Claudin-low subtype to the PAM50 classification
did not improve the ability to predict pCR in TNBC
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Fig. 1 Kaplan-Meier distant relapse-free survival analysis in the MDACC-based (GSE25066 [19]) dataset based on the pathological treatment
response. (a) Survival outcomes of the intrinsic subtypes in patients that achieved a pathological complete response (pCR); (b) Survival outcomes
of the risk of relapse score based on subtype and proliferation (ROR-P) groups in patients that achieved a pCR; (c) Survival outcomes of the intrinsic
subtypes in patients that did not achieve a pCR; (d) Survival outcomes of the ROR-P groups in patients that did not achieve a pCR
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TNBCtype association with chemotherapy response
in TNBC
Of the 350 TNBCs, 60 (17.1 %) were identified by the
TNBCtype online tool [26] as having high ESR1 levels
(Fig. 2) and thus were removed from many of the subse-
quent analyses because they are not considered a “class”
by the TNBCtype tool. The intrinsic subtype distribution
within this ESR1-high TNBCtype group was: Basal-like
(n = 20, 33.3 %), Normal-like (n = 17, 28.3 %), Luminal A
(n = 14, 23.3 %), Luminal B (n = 5, 8.3 %), and HER2-
enriched (n = 4, 6.7 %). As predicted, the levels of ESR1
mRNA in the TNBCtype ESR1-high group were signifi-
cantly higher than in the ESR1-low group; however, the
levels of ESR1 mRNA in the ESR1-high group were sig-
nificantly lower than in the group with clinically ER+
disease by IHC (Additional file 1: Figure S3).
The distribution of the PAM50 intrinsic subtypes
within the TNBCtype subgroups was similar to previous
reports where virtually all TNBCtype LAR tumors were
non-Basal-like (i.e. HER2-enriched or luminal), and 42 %
of MSL tumors were Normal-like (Additional file 1:
Table S8 and Figure S4-5). Of note, 12.1 % of TNBCs
subtyped by the TNBCtype (or 10.0 % of all TNBCs)
were identified as UNS, and 86.0 % of these were of the
Basal-like subtype by PAM50; thus, 27 % of the 350 clin-
ically defined TNBCs were not assigned a biological
group (i.e. either ESR1-high or UNS) by the TNBCtype
tool (Fig. 2).
Of the remaining 290 TNBC sample set (350 TNBC –
60 removed for high ESR1), 271 patients with TNBC
had response data (Additional file 1: Table S9). In this
subset, the TNBCtype classification was not found to be
Table 2 Cox model distant relapse-free survival (DRFS) analyses in patients with residual disease from the MDACC-based cohort
(GSE25066 [19])
Univariate analysis Multivariable analysis
Variables n % 5-yr DRFS HR Lower 95 % Upper 95 % P value HR Lower 95 % Upper 95 % P value
Age, years (cont. variable) – – – 1.0 0.98 1.01 0.590 0.98 0.97 1.01 0.129
Tumor size
T0-T2 216 56 % 74 % 1.0 – – – 1.0 – – –
T3-T4 173 44 % 61 % 2.1 1.38 3.07 <0.001 1.5 1.16 1.92 0.002
Node status
N0 126 32 % 85 % 1.0 – – – 1.0 – – –
N1-3 263 68 % 66 % 3.3 1.90 5.71 <0.001 2.9 1.62 5.37 <0.001
ER IHC
Positive 129 34 % 78 % 1.0 – – – 1.0 – – –
Negative 255 66 % 47 % 4.0 2.69 6.02 <0.001 1.8 0.87 3.56 0.114
PR IHC
Positive 175 46 % 79 % 1.0 – – – 1.0 – – –
Negative 208 54 % 54 % 3.3 2.15 5.05 <0.001 1.2 0.62 2.13 0.654
HER2 STATUS
Negative 373 99 % 68 % 1.0 – – – 1.0 – – –
Positive 3 1 % NA 1.1 0.16 8.16 0.900 0.5 0.07 3.65 0.485
Histological grade
1 28 8 % 96 % 1.0 – – – 1.0 – – –
2 160 44 % 73 % 6.1 0.83 44.43 0.076 2.75 0.36 20.94 0.33
3 175 48 % 60 % 10.9 1.51 78.73 0.018 2.54 0.33 19.66 0.37
PAM50
Luminal A 144 37 % 83 % 1.0 – – – 1.0 – – –
Luminal B 90 23 % 74 % 1.8 0.90 3.46 0.097 1.4 0.69 2.82 0.360
HER2-E 30 8 % 41 % 5.9 3.38 10.30 <0.001 2.7 1.15 6.41 0.023
Basal-like 102 26 % 48 % 5.3 2.63 10.84 <0.001 2.8 1.19 6.42 0.018
Normal-like 23 6 % 82 % 1.6 0.55 4.85 0.380 – – – –
HER2-E, HER2-enriched; pCR, Pathological complete response; ER, Estrogen receptor; PR, Progesterone receptor; IHC, Immunohistochemistry
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significantly associated with pCR in univariate (P =
0.762) or multivariable analyses (P = 0.836). Of note, only
eight patients had luminal A/B disease and their pCR
rate was 25 % versus 41 % in non-luminal (Basal-like
and HER2-enriched combined) tumors (OR = 0.477,
0.094–2.410).
Finally, we explored the ability of the TNBCtype classifi-
cation to predict pCR within TNBC if the ESR1-high sam-
ples were included as an eighth subtype (i.e. ESR1-high).
Interestingly, the pCR rate of the TNBCtype subtypes, as a
single group, was significantly higher than the pCR rate of
the ‘excluded’ TNBC ESR1-high group (39.9 % vs. 23.2 %,
OR = 2.970, 1.221–7.222). In the entire TNBC population
(n = 350), the TNBCtype classification that included the
ESR1-high group was found significantly associated with
pCR in multivariable analysis (P = 0.020) but not in uni-
variate analysis (P = 0.239). When the TNBCtype + ESR1-
high classification was included first in a multivariable
Table 3 Logistic regression model analyses of chemotherapy response in the combined cohorta
Univariate analysis Multivariable analysis
Signatures n pCR rate OR Lower 95 % Upper 95 % P value auROC OR Lower 95 % Upper 95 % P value auROC
Age, years (cont. variable) – – 1.0 0.97 1.00 0.027 0.547 0.99 0.97 1.01 0.178 0.744
Tumor size
T0-T2 556 24 % 1.0 – – – 0.519 1.0 – – –
T3-T4 353 12 % 0.8 0.55 1.02 0.071 0.6 0.50 0.84 0.001
ER IHC
Positive 487 11 % 1.0 – – – 0.679 1.0 – – –
Negative 415 37 % 4.7 3.39 6.61 <0.001 1.8 0.99 3.34 0.052
PR IHC
Positive 393 12 % 1.0 – – – 0.643 1.0 – – –
Negative 507 33 % 3.8 2.64 5.36 <0.001 1.1 0.65 1.89 0.716
HER2 STATUS
Negative 799 22 % 1.0 – – – 0.533 1.0 – – –
Positive 88 35 % 2.1 1.30 3.30 0.002 1.3 0.64 2.51 0.492
PAM50
Luminal A 281 6 % 1.0 – – – 0.719 1.0 – – –
Luminal B 168 16 % 3.0 1.57 5.64 0.001 3.3 1.72 6.45 <0.001
HER2-E 93 37 % 8.9 4.69 17.09 <0.001 6.1 2.75 13.38 <0.001
Basal-like 296 38 % 9.6 5.49 15.40 <0.001 6.1 2.94 12.66 <0.001
Normal-like 72 29 % 6.4 3.16 12.96 <0.001 – – – –
STUDY
HORAK 253 27 % 1.0 – – – 0.553 1.0 – – –
ISPY 54 31 % 1.2 0.65 2.32 0.532 1.3 0.55 3.16 0.540
MDACC508 488 20 % 0.7 0.48 0.97 0.032 0.9 0.58 1.33 0.526
MIYAKE 115 23 % 0.8 0.49 1.37 0.443 1.0 0.55 1.95 0.910
aOR, Odds ratio; auROC, Area under the receiver operating curve; HER2-E, HER2-enriched; pCR, Pathological complete response; ER, Estrogen receptor; PR, Progesterone
receptor; IHC, Immunohistochemistry
Table 4 Association of the intrinsic subtypes with chemotherapy response across the various pathology-based groups
All patients Luminal A Luminal B HER2-enriched Basal-like P value*
n pCR n pCR n pCR n pCR n pCR
All subgroups 838 23 % 281 6 % 168 16 % 93 37 % 296 38 % <0.001
HR+/HER2– 451 12 % 239 5 % 143 15 % 25 16 % 44 36 % <0.001
HER2+ 76 34 % 16 0 % 12 33 % 36 42 % 12 58 % 0.011
HR–/HER2– (TN) 292 37 % 19 26 % 8 0 % 30 47 % 235 37 % 0.011
*Likelihood ratio tests: adjusting clinical features: age, clinical stage, clinical nodal status and study cohort. Hormone receptors status and HER2 status were also
included in “all subgroups”
pCR, Pathological complete response; ER, Estrogen receptor; PR, Progesterone receptor
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model, addition of the PAM50 classification did not add
independent predictive information, but was trending
toward significance (P = 0.096). Similar results were ob-
tained if the PAM50 classification was included first into
the multivariable model and the TNBCtype + ESR1-high
classification was added second (P = 0.088).
Training and testing gene expression-based models
predictive of pCR
We explored the ability of newly derived gene expression-
based models to predict pCR in three different subgroups:
all patients, patients with Basal-like disease, and patients
with Luminal disease (Luminal A and B combined). To
accomplish this, we built a model in the MDACC-based
cohort (training dataset) and then tested the same model
on the other cohorts (testing datasets) (Additional file 1:
Figure S6-8).
In all patients, a gene expression-based model was iden-
tified in the MDACC-based cohort with an auROC of 0.80
(P <0.0001). This model predicted pCR in each testing
datasets with auROC between 0.67-0.75 (P <0.001), and in
the combined testing dataset (auROC 0.69, P <0.0001).
The gene signatures that composed the model and whose
high scores were associated with residual disease were
correlation to the Luminal A centroid, correlation to
PTEN present, and the Luminal A subtype (Additional
file 1: Figure S6). Conversely, the gene signatures that
composed the model and whose high scores were associ-
ated with pCR were correlation to the Basal-like centroid,
correlation to PTEN absent [28], a beta-catenin signature,
and a fetal mammary stem cell signature [29, 30].
In patients with Basal-like disease, a gene expression-
based model was identified in the MDACC-based cohort
(n = 166; auROC = 0.82, P <0.0001). This model pre-
dicted pCR in Horak et al. [19] (auROC 0.63, P = 0.018)
and in the combined cohort of testing sets (n = 130;
auROC 0.62, P = 0.011). Gene signatures that composed
the model and whose high score were associated with
residual disease were related to stromal/fibroblast-re-
lated biological processes (Additional file 1: Figure S7).
Conversely, gene signatures that composed the model
and whose high scores were associated with pCR were
associated with histone/chromatin remodeling.
Finally, in patients with Luminal disease, a gene
expression-based model was identified in the MDACC-
based cohort (n = 254; auROC = 0.82, P <0.0001). This
model predicted pCR in Miyake et al. [20] (auROC
0.76, P = 0.03) and in the combined cohort of testing
sets (n = 195; auROC 0.64, P = 0.014). The only gene
signature that composed the model and whose high
score was associated with residual disease was correl-
ation to TP53 wild-type status, whereas the only gene
signature that composed the model and whose high
score was associated with pCR was correlation to TP53
mutation (Additional file 1: Figure S8). Of note, both
TP53 signatures composed our previously reported
TP53 loss/mutation predictor [31].
Discussion
Herein, we evaluated the association of the intrinsic sub-
types of breast cancer with response and survival outcomes
in a large combined dataset of newly diagnosed patients
treated with multi-agent neoadjuvant chemotherapy and
we made the following observations. First, the intrinsic
subtypes of breast cancer provided independent prognostic
information beyond standard clinical-pathological vari-
ables. Second, within patients that do not achieve a
pCR, the ROR-P predictor can identify a group of pa-
tients with clinically node-negative disease with an
excellent survival outcome at 5-years. Third, the intrin-
sic subtypes predict pCR and their predictive value is
independent of standard clinicopathological variables.
Fourth, the Basal-like subtype identifies a group of
patients with a pCR rate >35 % across all pathology-
based cohorts evaluated, including TNBC. Fifth, neither
the identification of the Claudin-low subtype nor the
recently reported seven-TNBC subtype classification
predicted pCR within the large TNBC data set tested
here, whereas the Luminal versus non-Luminal separation
did predict pCR. Sixth, robust gene expression-based
models predictive of pCR can be identified within all
Fig. 2 Distribution of the TNBCtype, PAM50, and PAM50 + Claudin-low subtypes within 350 clinically-defined TNBCs
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patients, Basal-like disease, and Luminal disease; however,
additional validation of these new predictors is needed.
The intrinsic subtypes have previously been associated
with outcome in patients that have not received adjuvant
systemic therapy [32] and in patients that have received
adjuvant endocrine therapy-only [33–38]. More recently,
similar data has been observed in patients that have
received adjuvant multi-agent chemotherapy, including
CMF, anthracycline-based, and anthracycline/taxane-
based chemotherapy regimens [5, 8, 33]. Concordant
with the results of these studies, we observed an inde-
pendent association of the intrinsic subtypes with DRFS
in a population treated with cytotoxic and endocrine
therapy (if HR+). Interestingly, this association with out-
come was observed despite the fact that 20.3 % of the
patients in the Hatzis et al. [19] dataset had an outstand-
ing survival outcome at 5-years after achieving a pCR.
This data reaffirms the strong prognostic ability of intrin-
sic subtyping in the context of standard adjuvant therapy.
The prognostic abilities of the PAM50 ROR-P have
been clinically validated in two large retrospective co-
horts from the ABCSG08 and transATAC phase III
trials, where patients with surgically removed tumors re-
ceived adjuvant endocrine therapy only [36, 37]. In this
context, patients with a low ROR-P score have an out-
come of distant metastasis-free survival at 10-years of
97.5 % [32], and these patients might be safely spared
adjuvant (or neoadjuvant) chemotherapy. In our cohort
of patients treated with neoadjuvant cytotoxic and adju-
vant endocrine therapy (if HR+), ROR-P at diagnosis
independently predicted DRFS and identified a low risk
group of patients, especially within clinically node-negative
disease, with an outstanding outcome (DRFS >95 % at 5-
years). Similar results have been obtained with other prog-
nostic signatures tested in patients with early breast cancer
treated with and without multi-agent chemotherapy [39].
These nearly identical DRFS survival times with or without
chemotherapy suggest that the potential survival benefit
from neoadjuvant chemotherapy in patients with newly
diagnosed breast cancer that is clinically node-negative
and ROR-P low might be rather small, if any. In Hatzis
et al. [19], the proportion of patients with ROR-P low
within clinically node-negative disease was 26.8 %. If
the main objective of neoadjuvant chemotherapy is to
increase survival, then these patients with an outstanding
baseline prognosis should be spared the toxic side-effects
of chemotherapy and undergo surgical removal of their
tumors.
Molecular classification of TNBC into subgroups that
might be therapeutically relevant is an area of active and
ongoing research. For example, the PAM50 assay identi-
fies all the intrinsic molecular subtypes within TNBC, al-
though Basal-like disease predominates [40]. In addition,
we have identified and characterized a rare but relevant
intrinsic subtype known as Claudin-low [4]. Interestingly,
the intrinsic subtypes within TNBC share the same mo-
lecular features as the same subtypes within non-TNBC
with the exception of the TNBC HER2-enriched tumors
that do not show amplification of the ERBB2 17q ampli-
con [5, 41]. In our combined cohort of 350 TNBC cases,
intrinsic subtyping, and especially the luminal versus
non-luminal distinction, was found to be associated
with pCR following neoadjuvant chemotherapy. How-
ever, the addition of the Claudin-low classification to
the PAM50 classification did not improve these pCR
versus no pCR predictions.
In addition, Lehmann et al. [17] have classified TNBC
into seven subtypes (BL1, BL2, Immunomodulatory,
LAR, Mesenchymal, MSL and UNS). This seven-subtype
classification of TNBC has been found to be associated
with pCR in an independent cohort of 143 patients with
TNBC treated with anthracycline/taxane-based chemo-
therapy [18]. In our combined cohort of 290 TNBC
cases with seven-subtype information, the Lehmann
et al. [17] classification was not found to be significantly
associated with pCR. However, concordant with a previ-
ous report, BL1 showed the highest pCR rate (i.e. 47 %)
and BL2 the lowest pCR rate (i.e. 28 %). Surprisingly, the
LAR group, which was found to have a 10 % (2/20) pCR
rate in a previous report [18], showed a 37 % pCR rate
in this larger combined cohort. This difference might be
due to the fact that 71.4 % (20/28) of LAR tumors in our
combined cohort were of the HER2-enriched subtype, a
group of tumors highly responsive to chemotherapy, and
only 17.9 % (5/28) were of the Luminal A/B subtype.
Two important issues of the Lehmann et al. [17] classifi-
cation need to be taken into account. First, this classifica-
tion ignores the Normal-like/normal tissue distinction. In
other words, triple-negative tumors that are highly con-
taminated with normal breast tissue, which represent
11–16 % of the samples found in publicly available
microarray datasets [17], are now classified into “tumor”
subtypes. Whereas PAM50 identifies these tumors as being
more similar to true normal breast samples (i.e. Normal-
like) than to any tumor subtype, the Lehmann et al. [17]
classification calls them as if they were a tumor (mostly
MSL), although the Normal-like samples can also be ob-
served in other subtype categories [40, 42]. Second, a sub-
stantial proportion of TNBC samples (~13–16 %) coming
from the Lehmann et al. [17] classification were either not
considered to be TNBC by gene expression and are re-
moved (i.e. ESR1-high), or they fall into the unclassified or
unstable (UNS) group, which is composed of a mix of
tumors that only share the feature that they cannot be clas-
sified into one of the other six tumor subtypes.
This study also has other limitations that need to be
highlighted. First, this was a retrospective and explora-
tory analysis of four datasets of patients treated with
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multi-agent chemotherapy; thus, we did not test a pre-
specified hypothesis. Second, we used the research-based
version of the PAM50 assay and not the standardized
version that is currently commercially available. Third,
we could not evaluate the predictive ability of the intrin-
sic subtypes to specific regimens or schedules. Fourth,
we used the pathological data as provided in each publi-
cation and different definitions and cutoffs might have
been used to determine the positivity of each biomarker.
Thus, the results might have differed if ER, PR, and
HER2 status had been centrally confirmed. Nonetheless,
we and others have reported that, even within centrally
confirmed TNBC, all the intrinsic molecular subtypes
can be identified [15]. Fifth, Ki-67 by IHC was not available
in any of the four datasets and thus we could not explore
the ability of this biomarker to predict pCR following
chemotherapy or survival outcome in the presence of the
intrinsic subtypes or histological grade [43], especially
within HR+/HER2– disease. Sixth, the survival outcomes
were only available in one of the datasets evaluated. Finally,
the cutoffs to define the three risk groups of ROR-P were
based on a large node-negative cohort that did not receive
adjuvant systemic therapy [24]. These cutoffs might differ
from the current standardized PAM50 version that takes
into account tumor size and that defines the low risk group
as those patients with a risk of distant relapse at 10-years
below 3 % [36, 37].
Conclusion
To conclude, intrinsic subtyping at diagnosis provides use-
ful prognostic and predictive information for neoadjuvant
chemotherapy-treated patients. The absolute benefit of
chemotherapy in early breast cancer with clinically node-
negative disease might be low if predicted to be ROR-P
low risk at diagnosis. Further studies are needed to deter-
mine the role of intrinsic subtyping in treatment decision-
making at diagnosis of breast cancer.
Availability of data and materials
Four clinically annotated microarray-based breast can-
cer datasets were evaluated from the public domain
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can be found in Additional file 2: Supplemental Data.
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